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ABSTRACT
Introduction: Many antidepressants are indicated for
the treatment of major depression. Two network meta-
analyses have provided the most comprehensive
assessments to date, accounting for both direct and
indirect comparisons; however, these reported
conflicting interpretation of results. Here, we present a
protocol for a systematic review and network meta-
analysis aimed at updating the evidence base and
comparing all second-generation as well as selected
first-generation antidepressants in terms of efficacy and
acceptability in the acute treatment of major
depression.
Methods and analysis: We will include all
randomised controlled trials reported as double-blind
and comparing one active drug with another or with
placebo in the acute phase treatment of major
depression in adults. We are interested in comparing
the following active agents: agomelatine, amitriptyline,
bupropion, citalopram, clomipramine, desvenlafaxine,
duloxetine, escitalopram, fluoxetine, fluvoxamine,
levomilnacipran, milnacipran, mirtazapine, nefazodone,
paroxetine, reboxetine, sertraline, trazodone,
venlafaxine, vilazodone and vortioxetine. The main
outcomes will be the proportion of patients who
responded to or dropped out of the allocated
treatment. Published and unpublished studies will be
sought through relevant database searches, trial
registries and websites; all reference selection and data
extraction will be conducted by at least two
independent reviewers. We will conduct a random
effects network meta-analysis to synthesise all
evidence for each outcome and obtain a
comprehensive ranking of all treatments. To rank the
various treatments for each outcome, we will use the
surface under the cumulative ranking curve and the
mean ranks. We will employ local as well as global
methods to evaluate consistency. We will fit our model
in a Bayesian framework using OpenBUGS, and
produce results and various checks in Stata and R.
We will also assess the quality of evidence contributing
to network estimates of the main outcomes with the
GRADE framework.
Ethics and dissemination: This review does not
require ethical approval.
PROSPERO registration number:
CRD42012002291.
BACKGROUND
Major depressive disorder (MDD) is the most
prevalent psychiatric disease in the general
Strengths and limitations of this study
▪ We will conduct a random effects network meta-
analysis to synthesise all available evidence
(either published or unpublished) for each pre-
specified outcome, and obtain a comprehensive
ranking of all treatments.
▪ We will employ local as well as global methods
to evaluate consistency and we will explore
whether treatment effects are robust in network
meta-regression.
▪ This will be the largest network meta-analysis (in
terms of number of studies and patients) ever
conducted in psychiatry and the most compre-
hensive analysis for the greatest number of anti-
depressants in major depression. The findings
from this study have the potential to guide treat-
ment decisions and guideline development.
▪ The risk of publication bias and the risk of selec-
tion bias are high in antidepressant trials, in par-
ticular with placebo-controlled trials.
▪ The limitations of primary studies will be
addressed with the Cochrane risk of bias tool
and the quality of evidence for network estimates
of the main outcomes will be assessed with the
GRADE framework.
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population, affecting more than 16% of adults during their
lifetime.1 In 2000, the economic burden of depressive disor-
ders in the USA was estimated to be around 80 billion
dollars, with more than 30% of these costs being attribut-
able to direct medical expenses.2 Pharmacotherapy plays an
important role in the management of major depression.
Before the late 1980s, pharmacological treatment was
limited to tricyclic antidepressants (TCAs) and mono-
amine oxidase inhibitors (MAOIs). TCAs and MAOIs
sometimes are referred to as traditional or ﬁrst-generation
antidepressants. These drugs are often accompanied by
multiple side effects that many patients ﬁnd intolerable.
TCAs tend to cause anticholinergic effects including dry
mouth and eyes, urinary hesitancy or and sometimes
even retention, and constipation, and MAOIs have the
potential to produce hypertensive crises if taken along
with certain foods or dietary supplements containing tyr-
amine. However, even though ﬁrst-generation antidepres-
sants are no longer agents of choice in many
circumstances, TCAs are still used worldwide, especially in
low and middle income countries; according to the list of
essential medicines issued by the WHO, amitriptyline is
one of the two available treatment options for major
depression, along with an selective serotonin reuptake
inhibitors (SSRI) ﬂuoxetine.3
Newer antidepressants include SSRIs, serotonin and nor-
epinephrine reuptake inhibitors (SNRIs), and other
second-generation drugs. The ﬁrst of the second-
generation drugs was introduced to the US market in
1985, when bupropion was approved for the treatment of
major depressive disorders. In 1987, the US Food and
Drug Administration (FDA) approved the ﬁrst SSRI,
ﬂuoxetine. Since then, ﬁve other SSRIs have been intro-
duced into the market between 1991 and 2002: sertraline,
paroxetine, citalopram, ﬂuvoxamine and escitalopram.
The SNRIs were ﬁrst introduced in 1993 with the
approval of venlafaxine. In 1994, nefazodone, which is
essentially an SSRI with additional 5-hydroxytryptamine-2
(5-HT2) and 5-hydroxytryptamine-3 (5-HT3) antagonist
properties, was FDA approved. Mirtazapine, a drug that
exhibits both noradrenergic and serotonergic activity with
central autoreceptors, was added in 1996 and duloxetine,
an SNRI, was approved for the treatment of MDD (and
diabetic peripheral neuropathic pain) in 2004. The latest
second-generation antidepressants approved for the treat-
ment of MDD in adults include desvenlafaxine, the major
active metabolite of venlafaxine; agomelatine, a melato-
nergic agonist with 5-HT2 antagonism; and vortioxetine,
a serotonin modulator and stimulator.i Several systematic
reviews have assessed the comparative efﬁcacy and safety
of second-generation antidepressants, but two recent
comparative effectiveness reviews have provided the most
comprehensive assessments to date, notwithstanding con-
ﬂicting interpretation of results.4 5
Network meta-analysis (NMA) is a statistical technique
that allows both direct and indirect comparisons to be
undertaken, even when pairs of the treatments have not
been compared directly (head-to-head) in the same
trial.6–8 NMA can summarise randomised controlled
trials (RCTs) of several different treatments by providing
point estimates for their association, with a given end
point as well as an estimate of inconsistency (ie, a
measure of how well the entire network ﬁts together,
with small values suggesting better internal agreement
of the model). NMA has already been used successfully
in other ﬁelds of medicine9 and psychiatry.4 10–12
The objective of this systematic review and NMA is to
compare all second-generation as well as selected ﬁrst-
generation antidepressants (refer Types of interventions
section) in terms of efﬁcacy and acceptability in the
acute treatment of major depression in adults to better
inform clinical practice and mental health policies. The
project is called Group of Researchers Investigating
Speciﬁc Efﬁcacy of individuaL Drugs for Acute depres-
sion (GRISELDA) and will be based on our previous
NMA on antidepressants;4 however the present review
differs in that it will enlarge the number of antidepres-
sants under investigation, add new and clinically inform-
ative outcome measures, and particularly include
placebo-controlled trials.
METHODS AND ANALYSIS
Criteria for considering studies for this review
Types of studies
All RCTs reported as double-blind comparing one
active drug with another or with placebo in the acute
phase treatment of major depression will be included.
Only monotherapy studies will be included; thus RCTs
in which antidepressants were used as an augmenta-
tion strategy will be excluded. Quasi-randomised trials
(such as those allocating by using alternate days of
the week) will be excluded. Cross-over and cluster
randomised trials will be included. We will not
include studies where sequence generation was at
high risk of bias, or where the allocation was clearly
not concealed.
Types of participants
Patients aged 18 years or older, of both sexes, with a
primary diagnosis of major depression will be included.
Studies adopting any standard operationalised diagnostic
criteria to deﬁne patients suffering from unipolar major
depression will be included, such as Feighner criteria,
Research Diagnostic Criteria, DSM-III, DSM-III-R,
DSM-IV, DSM-5 and ICD-10. Studies in which 20% or
more of the participants may be suffering from bipolar
or psychotic depression will be excluded. A concurrent
iThe mechanism of the antidepressant effect of vortioxetine is not fully
understood, but is thought to be related to its enhancement of
serotonergic activity in the central nervous system through inhibition
of the re-uptake of serotonin (5-HT). It also has several other activities,
including 5-HT3 receptor antagonism and 5-HT1A receptor agonism.
The contribution of these activities to vortioxetine’s antidepressant
effect has not been established.
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secondary diagnosis of another psychiatric disorder will
not be considered as exclusion criterion, but RCTs in
which all participants have a concurrent primary diagno-
sis of another mental disorder will be excluded. Studies
in which all participants have a diagnosis of resistant
depression will be excluded. Antidepressant trials in
depressive patients with a serious concomitant medical
illness will be excluded. RCTs of women with post-
partum depression will be also excluded, because post-
partum depression appears to be clinically different
from major depression.13 Trials which allow rescue medi-
cations will be included so long as these are equally pro-
vided among the randomised arms.
Types of interventions
We are interested in comparing the following active
agents: agomelatine, amitriptyline, bupropion, citalo-
pram, clomipramine, desvenlafaxine, duloxetine, escita-
lopram, ﬂuoxetine, ﬂuvoxamine, levomilnacipran,
milnacipran, mirtazapine, nefazodone, paroxetine,
reboxetine, sertraline, trazodone, venlafaxine, vilazo-
done and vortioxetine. We will include all the second
generation antidepressants, and of older agents, we have
selected the two tricyclics included in the WHO3 list of
essential medicine: (1) amitriptyline, recommended for
major depression and (2) clomipramine, although a
typical tricyclic antidepressant, as it has a different bio-
chemical, mainly serotonergic, action. We also selected
trazodone and nefazodone because these are believed to
have very distinct effect and tolerability proﬁles.14 We
will include only studies randomising patients to the
drug within its licensed dose range.4 If a study included
arms with both unapproved and approved doses, we
include the study but only the arms that used the thera-
peutic doses.15
We will obtain information about the interventions of
interest either from head-to-head or placebo controlled
trials. Hence the synthesis comparator set consists of all
the interventions listed above and placebo controlled
trials. Figure 1 shows the network of all possible pair-
wise comparisons between the eligible interventions.
We anticipate that any patient who meets all inclusion
criteria is, in principal, equally likely to be randomised
to any of the interventions in the synthesis comparator
set.
Outcome measures
Considering that clinical trials of antidepressant drugs
are usually small and that data distribution is difﬁcult to
assess for studies with small samples, in this review prior-
ity will be given to the use and analysis of dichotomous
variables both for efﬁcacy and acceptability.
▸ Primary outcomes
(1) Efﬁcacy (as dichotomous outcome)—response
Measured by the total number of patients who
had a reduction of at least 50% on the total score
between baseline and week 8 (range 4–12 weeks)
on a standardised observer-rating scale for depres-
sion. We will employ Hamilton Depression Rating
Scale (HDRS) or, if HDRS was not used, another
standardised and validated observer-rating scale.
Any version of HDRS will be accepted.
Figure 1 Network of all possible pairwise comparisons between the eligible interventions.
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(2) Acceptability of treatment
Treatment discontinuation (acceptability) is
deﬁned as the proportion of patients who leave
the study early for any reason during the ﬁrst
8 weeks of treatment (range 4–12 weeks).
▸ Secondary outcomes
(3) Efﬁcacy (as continuous outcome)
Measured by the end point score on the HDRS or
Montgomery-Åsberg Depression Rating Scale
(MADRS), if HDRS was not used, after 8 weeks
(range 4–12 weeks). If none of the former scales
is used, we will consider other standardised rating
scales. When end point scores are not reported
but change scores are, we will use the latter
scores.16 See ﬁgure 2 for full details about the
data extraction process (decision tree).
(4) Efﬁcacy (as dichotomous outcome)—remission
Measured by the total number of patients who
had a remission of depressive symptoms between
baseline and week 8 (range 4–12 weeks) on a
standardised rating scale for depression (HDRS
or another standardised rating scale, if HDRS
was not used). Remission will be deﬁned as
score of less or equal to 7 or 8 on the 17-item
HDRS (or the corresponding threshold for
longer versions of HDRS),17 or of less or equal
to 10 or 11 on the MADRS scale at week 8
(range 4–12 weeks).18
(5) Tolerability of treatment
The proportion of patients who leave the study
early due to adverse events during the ﬁrst
8 weeks of treatment (range 4–12 weeks).
Search strategy and study selection
Searches for published RCTs will be undertaken in the
following electronic databases: CENTRAL, CINAHL,
EMBASE, LiLACS, MEDLINE, MEDLINE In-Process and
Figure 2 Decision-tree for data extraction of continuous efficacy outcome. HDRS: Hamilton Depression Rating Scale; MADRS:
Montgomery-Åsberg Depression Rating Scale.
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PSYCINFO. The electronic search will be supplemented
with manual searches for published, unpublished and
ongoing RCTs in the following drug-approval agencies:
the Food and Drug Administration (FDA) in the USA,
the Medicines and Healthcare products Regulatory
Agency in the UK, the European Medicines Agency
(EMA) in the European Union, the Medicines
Evaluation Board in the Netherlands, the Medical
Products Agency in Sweden, the Pharmaceuticals and
Medical Devices Agency (PMDA) in Japan, and the
Therapeutic Goods Administration (TGA) in Australia.
We will also undertake searches for published, unpub-
lished and ongoing studies in a range of research regis-
tries (see online supplementary appendix for the full list
of resources). It is important to include unpublished
data, since publication bias leads to exaggerated effect
sizes15 and reporting bias can bias NMA-based estimates
of treatments efﬁcacy and modify ranking.17 Studies will
be identiﬁed using search terms for depression (depress*
or dysthymi* or adjustment disorder* or mood disorder* or
affective disorder or affective symptoms) appended to the list
of antidepressants under review. No data limits or lan-
guage restrictions will be applied to any of the searches.
The reference lists of included studies will be
searched for additional studies. Where eligible studies
are found, unpublished data will be requested from the
investigators. We will also contact the National Institute
for Health and Care Excellence (NICE, UK), the
Institut für Qualität und Wirtschaftlichkeit intramuscular
Gesundheitswesen (IQWiG, Germany), and any other
relevant organisations and individuals for any additional
information not already identiﬁed. We are aware that
there are many RCTs published in Chinese journals.
However, in many of these studies only incomplete or
conﬂicting information is available, and it has been
reported that many of them do not use appropriate ran-
domisation procedures.19 In an effort to avoid the
potential biases that may be introduced by including
these trials without further information, we will not
search the Chinese databases. However, to be consistent
in our selection procedure, we will include all studies,
irrespective of their country of origin, identiﬁed in the
international databases listed above and satisfying our
eligibility criteria.
Two persons will independently review references and
abstracts retrieved by the search. If both reviewers agree
that a trial does not meet eligibility criteria, it will be
excluded. We will obtain the full text of all remaining
articles and use the same eligibility criteria to determine
which, if any, to exclude at this stage. Any disagreements
will be resolved via discussion with a third member of
the review team.
Data extraction
Two reviewers will then independently read each article/
study report, evaluate the completeness of the data
abstraction and conﬁrm the quality rating (see details
below). We will design and use a structured data
extraction form to ensure consistency of information and
appraisal for each study. Information extracted will
include study characteristics (such as lead author, publi-
cation year and journal), participant characteristics (such
as diagnostic criteria for depression, age, sex, setting and
severity of depression), intervention details (such as drug
dose and dosing schedule (ﬁxed vs ﬂexible)), and
outcome measures. Two review authors will ascertain that
the data are entered correctly into the ﬁnal data set.
When published and unpublished studies provide differ-
ent values, we will prioritise the unpublished data.15
Dichotomous outcomes
We opt for the number of successes and failures per
treatment arm as deﬁned in Outcome measures section.
When these numbers are not reported but baseline mean
and end point mean and SDs of the depression rating
scales (such as HDRS or MADRS) are provided, we will
calculate the number of responding patients at 8 weeks
(range 4–12 weeks) by employing a validated imputation
method.20 Below we also discuss our strategy when means
and/or SDs are not reported in the articles.
Continuous outcomes
We will extract means, SDs, and numbers of patients ran-
domised in each study arm. When means and their SDs
are not recorded, authors will be asked to supply the
data. When SEs, t-statistics or p values are reported,
these will be transformed to SDs. If SDs are not reported
and not provided by the authors, the mean value of
known SDs will be calculated from the group of
included studies according to Furukawa and collea-
gues.21 When mixed method repeated measures or
other appropriate imputation methods are used,22 we
will prefer these results. When data on dropouts are
carried forward and included in the evaluation (Last
Observation Carried Forward, LOCF), these will be ana-
lysed according to the primary studies.
Missing outcome data
Outcomes of patients who leave the study early are typic-
ally imputed by the trialists, often using LOCF.23 It is
very rare for an article to report the outcome separately
for fully observed and imputed data, and the summary
statistics that we will collect are bound to refer to both
completers and patients who dropped out. The appro-
priateness of the imputation method to account for
early dropouts will be considered in the Risk of bias
assessment section. During the protocol development
process, we have carried out some exploratory analyses
to assess the comparability between studies with placebo
arm and studies with only active treatments. Considering
that the number of dropouts is usually higher in placebo
controlled trials,24 we anticipate that the imputation of
missing outcome data using LOCF can be problematic
when comparing head-to-head with placebo trials within
the same network of treatments. In case of material dif-
ferences between these types of studies, we will carefully
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investigate this methodological issue, and try to address
it properly from a statistical point of view (refer Risk of
bias assessment section).
After imputations at the individual participant level by
the original authors, the outcome might be unknown
(and not imputed by the original authors) for a very
small proportion of study participants. For the dichot-
omous efﬁcacy outcome, we will ﬁrst assume that partici-
pants with an unknown outcome are non-responders.
Although this corresponds to naive imputations24 an
extensive sensitivity analysis using more appropriate
methods to account for missing outcome data in anti-
depressant trials has shown that imputing outcomes for
a very small percentage of patients (as in our case) has
no material impact on the results.25 For continuous out-
comes, participants with missing outcome data will be
excluded from the analysis.
Unit of analysis issues
We will extract data from cross-over studies using only
the ﬁrst period because carry-over effects can be import-
ant in antidepressant trials.26 In cluster randomised
trials, we will extract data that account for the clustering
in the results (eg, from multilevel models). If such
adjusted results are not available, we will extract
unadjusted data and will adjust the sample size (in the
continuous outcomes) and both the sample size and
number of events (in the dichotomous outcomes) by
dividing it with the design effect.27
Length of trial
Clinically, whether efﬁcacy is assessed after 8 weeks of
treatment or after 16–24 weeks or more may lead to dif-
ferences in terms of assessed treatment outcome.
Clinicians need to know whether (and to what extent)
treatments work within a clinically reasonable period of
time. Unfortunately, there is no consensus on what the
appropriate duration of an acute phase trial is. In the
present review, acute treatment will be deﬁned as an
8-week treatment in both the efﬁcacy and acceptability
analyses.4 If 8-week data are not available, we will use
data as close to 8 weeks as possible (ranging between 4
and 12 weeks). Longer term studies will be included in
the systematic review, but excluded from the statistical
synthesis of data if they do not provide data for the
4–12 weeks period.
Comparability of dosages
We will include only study arms randomising patients to
drugs within the licensed dose. Both ﬁxed-dose and
ﬂexible-dose designs will be allowed.4 There is a possibil-
ity that some trials compare one agent at the upper limit
of its therapeutic range with another agent at the lower
limit of its therapeutic range within the same study. We
plan to capture this study characteristic by adding a
dichotomous variable indicating whether dosages are
comparable, and use this information for a sensitivity
analysis.
Risk of bias assessment
We will assess risk of bias in the included studies using
the tool described in the Cochrane Collaboration
Handbook as a reference guide.28 The assessment will
be performed by two independent raters. If the raters
disagree, the ﬁnal rating will be made by consensus with
the involvement (if necessary) of another member of
the review group. We will evaluate the risk of bias in the
following domains: generation of allocation sequence,
allocation concealment, blinding of study personnel and
participants, blinding of outcome assessor, attrition,
selective outcome reporting and other domains, includ-
ing sponsorship bias. Where inadequate details of alloca-
tion concealment and other characteristics of trials are
provided, the trial authors may be contacted in order to
obtain further information.
Selective outcome reporting will be rated with
regard to the two primary outcomes in the systematic
review. It will be rated at low risk of bias if the number
of responders is reported (or if the continuous
outcome measures of depression severity are reported
in enough details to enable imputation of the number
of responders), and if the number of total dropouts is
reported. It will be rated at high risk of bias if neither
is reported, and will be rated as unclear risk of bias
otherwise.
Losses to follow-up are typically associated with the
outcome and the treatment received. Patients tend to
leave a trial early because of early response, side
effects or lack of response. Consequently, missingness
is typically informative in antidepressant trials.
Inappropriate methods to impute data (such as the
LOCF approach) are often applied and are known to
produce biased results.22 However, even appropriate
methods (such as multiple imputations) when applied
in practice often use the missing at random assump-
tion, which is often difﬁcult to defend. Consequently,
we will classify the studies with respect to attrition bias
as being: (1) at low risk if an appropriate imputation
method has been employed that accounts for the dif-
ferent reasons for dropout between arms (especially
in placebo-controlled trials, where the lack of active
comparator can affect dropout rates in a speciﬁc way),
or if the percentage of missing outcome data is 20%
or less overall and is balanced between arms (ie, abso-
lute difference in dropouts <5% for active comparison
and <10% for placebo comparison); (2) at high risk of
bias if dropout is unbalanced between the arms, and
an inappropriate imputation method (eg, LOCF) has
been used to impute dropouts. All other cases will be
classiﬁed as unclear risk of bias. Studies will be classi-
ﬁed as having low risk of bias if none of the domains
above was rated as high risk of bias and three or less
were rated as unclear risk; moderate if one was rated
as high risk of bias or none was rated as high risk of
bias but four or more were rated as unclear risk, and
all other cases will be assumed to pertain to high risk
of bias.
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Statistical synthesis of study data
Characteristics of included studies and information flow in
the network
We will generate descriptive statistics for the trial, and
study population characteristics across all eligible trials,
describing the types of comparisons and some important
variables, either clinical or methodological (such as year
of publication, age, severity of illness, sponsorship and
clinical setting).
The available evidence will be presented in the
network diagram. The size of the nodes will reﬂect the
amount of evidence accumulated for each treatment
(total number of patients), the breadth of each edge will
be proportional to the inverse of the variance of the
summary effect of each direct treatment comparison,
and the colour of each edge will represent risk of bias
(low, moderate or high, refer Risk of bias assessment
section). To understand which are the most inﬂuential
comparisons in the network and how direct and indirect
evidence inﬂuences the ﬁnal summary data, we will use
the contribution matrix that describes the percentage
contribution of each direct meta-analysis to the entire
body of evidence.29 30
Pairwise meta-analyses
For each pair-wise comparison, we will synthesise data
to obtain summary standardised mean differences
(SMD, Cohen’s d) for continuous outcomes or ORs for
dichotomous outcomes, both with 95% Credible
Intervals (CrI). We will use a random effects model to
incorporate the assumption that the different studies are
estimating different, yet related, treatment effects.27 For
each outcome, we will ﬁrst assume that each pairwise
meta-analysis comparing treatments X and Y has its own
heterogeneity variance parameter t2XY and then assume
that there are two heterogeneity parameters; one
common for all placebo-controlled trials ðt2PÞ and one
for all active versus active comparisons ðt2AÞ. Visual
inspection of the forest plots and monitoring of the pos-
terior distributions of t2P, t
2
XY and t
2
A will be used to
investigate the possibility of statistical heterogeneity. The
posterior distributions of the heterogeneity parameters
will be compared to their predictive distributions, as
described elsewhere.31 32 Finally the I2 statistic and its
95% CrI will be calculated to convey the amount of
heterogeneity.
Assessment of the transitivity assumption
Transitivity, which is the key underlying assumption of
NMA, will be investigated carefully. Joint analysis of treat-
ments can be misleading if the network is substantially
intransitive. We will need to investigate the distribution
of clinical and methodological variables that can act as
effect modiﬁers across treatment comparisons.33 The
clinical features, which have been demonstrated to date
to moderate efﬁcacy of antidepressants include bipolar-
ity,34 psychotic features,35 and subthreshold depres-
sion.36 We have assured transitivity in our network with
regard to these variables by limiting our samples to parti-
cipants with non-psychotic unipolar major depression.
Other clinical or methodological variables that may
inﬂuence our primary outcomes of antidepressant efﬁ-
cacy or acceptability include: age, depressive severity at
baseline,37 38 and the dosing schedule.39 We will investi-
gate if these variables are similarly distributed across
studies grouped by comparison. The inclusion of
placebo and concerns about its potential to violate the
transitivity assumption have been highlighted in
general7 8 and particularly in depression studies.40 41
Consequently, the comparability of placebo-controlled
studies with those that provide head-to-head evidence
will be examined carefully.
Network meta-analyses
We assume that patients who fulﬁl the inclusion criteria
outlined in Criteria for considering studies for this
review section are equally likely to be randomised to any
of the antidepressants that we plan to compare. If the
collected studies appear to be sufﬁciently similar with
respect to the distribution of effect modiﬁers (refer
Assessment of transitivity assumption section), we will
conduct a random effects NMA to synthesise all evi-
dence for each outcome, and obtain a comprehensive
ranking of all treatments. We will use arm-level data and
the binomial likelihood for dichotomous outcomes. We
will account for the correlations induced by multiarm
studies by employing multivariate distributions. We will
assume a single heterogeneity parameter for each
network. We will present the summary ORs or SMD for
all pairwise comparisons in a league table. We will also
estimate the prediction intervals to assess how much the
common heterogeneity affects the relative effect with
respect to the extra uncertainty anticipated in a future
study. To rank the various treatments for each outcome,
we will use the surface under the cumulative ranking
curve (SUCRA) and the mean ranks.42
Assessment of inconsistency
The strategical and conceptual evaluation of transitivity
will be supplemented with a statistical evaluation of con-
sistency, the agreement between direct and indirect evi-
dence. We will employ local as well as global methods to
evaluate consistency.43 Local methods detect ‘hot spots’
of inconsistency, evidence loops that are inconsistent or
comparisons for which direct and indirect evidence dis-
agree. We will employ the loop-speciﬁc approach to
evaluate inconsistency within each loop of evidence,44
and a method that separates direct evidence from indir-
ect evidence provided by the entire network.45 We will
also evaluate consistency in the entire network by calcu-
lating the I2 for network heterogeneity, inconsistency,
and for both.46 47
Tests for inconsistency are known to have low power,48
and empirical evidence has suggested that 10% of evi-
dence loops published in the medical literature are
expected to be inconsistent.49 Therefore, interpretation
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of the statistical inference about inconsistency will be
carried out with caution and possible sources of incon-
sistency will be explored even in the absence of evidence
for inconsistency.
Exploring heterogeneity and inconsistency and sensitivity
analyses
We expect small amounts of heterogeneity and inconsist-
ency to be present given the variety of study settings we
plan to include. We will explore whether treatment
effects for the two primary outcomes are robust in sub-
group analyses and network meta-regression using the
following characteristics: (1) study year; (2) sponsorship;
(3) depressive severity at baseline; (4) dosing schedule;
(5) response to placebo; (6) proportion of participants
allocated to placebo; number of recruiting centres
(single-centre vs multicentric studies).50 51 The sensitiv-
ity of our conclusions for the two primary outcomes will
be evaluated by analysing (1) only studies with reported
SD rather than imputed; (2) only studies with balanced
doses in all arms (ie, we will exclude studies with
unfair dose comparisons); (3) only studies with unpub-
lished data (ie, we will exclude studies providing pub-
lished data only); (4) only studies with low risk of bias
(as deﬁned in Risk of bias assessment section); (5) only
head-to-head studies.
Selection bias
The risk of selection bias is high in antidepressants
trials, in particular with placebo-controlled trials.15 We
will use the comparison-adjusted30 and contour-
enhanced52 funnel plots to investigate whether results in
imprecise trials differ from those in more precise trials.
We will also run network meta-regression models to
detect associations between study size and effect size.53 If
an important association is found and publication bias is
suspected, we will attempt to explore the possibility that
funnel plot asymmetry is due to publication bias by
employing a selection model.54
Model implementation
We will ﬁt our model using OpenBUGS55 and Stata
(StataCorp. 2015. Stata Statistical Software: Release 14.
College Station, TX: StataCorp LP). For the Bayesian
implementation we will employ the binomial likelihood
for dichotomous outcomes and will use uninformative
prior distributions for the treatment effects, that is, N
(0,1000), and a minimally informative prior distribution
for the common heterogeneity SD depending on the
outcome, that is, U(0,5). Also, we will assume unin-
formative priors, that is, N(0,1000) for all
meta-regression coefﬁcients. To check convergence, we
will run multiple chains and monitor their mixing; we
will use the Brooks-Gelman-Rubin diagnostic.
Analyses for statistical evaluation of the inconsistency
and production of network graphs and result ﬁgures will
be carried out in Stata using the mvmeta command56
and a collection of routines described elsewhere.30 All
analyses of the primary outcomes will be duplicated
using the netmeta package in R.57
GRADE quality assessment of all comparisons in the
network
We will also assess the quality of evidence contributing
to network estimates of the main outcomes with the
GRADE framework, which characterises the quality of a
body of evidence on the basis of the study limitations,
imprecision, inconsistency, indirectness and publication
bias.43 The starting point for conﬁdence in each
network estimate is high, but will be downgraded accord-
ing to the assessments of these ﬁve domains.
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